Non small cell lung cancer historical perspective

Jump to navigation Jump to search

Non Small Cell Lung Cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Non Small Cell Lung Cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-Ray

CT Scan

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Management Approach

Stage I
Stage II
Stage III
Stage IV
Metastatic Cancer

Medical Therapy

Chemotherapy
Radiation Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Non small cell lung cancer historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Non small cell lung cancer historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Non small cell lung cancer historical perspective

CDC on Non small cell lung cancer historical perspective

Non small cell lung cancer historical perspective in the news

Blogs on Non small cell lung cancer historical perspective

Directions to Hospitals Treating Non small cell carcinoma of the lung

Risk calculators and risk factors for Non small cell lung cancer historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Trusha Tank, M.D.[2] Maria Fernanda Villarreal, M.D. [3]

Overview

Lung cancer was not identified as a disease until 1700. Morgagni GB, an Italian anatomist, first described lung cancer in his book "De sedibus et causis morborum per anatomen indagatis (1761)". In 1761, Dr. John Hill of London, proved the relationship between the use of tobacco and cancer in his case study. In 1879, Harting and Hesse, two German physicians, first described the association between lung cancer and working in mines, and later radon gas was identified as the cause. In 1929, Fritz Lickint, a German physician first described the association between smoking and lung cancer. In 1965, U.S. Congress adopted the Federal Cigarette Labeling and Advertising Act and the Public Health Cigarette Smoking Act of 1969 as a preventive measure against lung cancer.

Historical Perspective

Discovery

  • In 1761, Dr. John Hill of London, proved the relationship between the use of tobacco and cancer in his case study.[1]
  • In between 1876 to 1938 miners working in silver, later nickel, cobalt, bismuth, and arsenic mines were dying from a disease called “Bergkrankheit” (mountain sickness) that lasted for about 25 years, which later confirmed was the lung cancer.[2]
    • Later in 1924 German physics journal confirmed the cause behind the deaths in miners was radon gas.
  • In 1879, Harting and Hesse, two German physicians, first described the association between lung cancer and working in mines.[3]
  • In 1929, Fritz Lickint, a German physician first described the association between smoking and lung cancer.
    • This discovery led to anti-smoking movement in Germany.
  • In 1950, "The British Doctors Study" was the first solid epidemiological evidence of the link between lung cancer and smoking.[4]
  • In 1965, the first preventive measures against lung cancer were implemented in The United States.[5]
    • U.S. Congress adopted the Federal Cigarette Labeling and Advertising Act of 1965 and the Public Health Cigarette Smoking Act of 1969. These laws:
    • Required a health warning on cigarette package.
    • Banned cigarette advertising in the broadcasting media.
    • Called for an annual report on the health consequences of smoking.
  • In 1982, Geoffrey Cooper, an American pathologist first used the NIH 3T3 focus assay to identify the activated K-ras oncogene in lung cancer cell lines.[6]
  • In 1987, it was established that a receptor on cancer cells called the epidermal growth factor receptor (EGFR) plays an important role in the growth and spread of non small cell lung cancer.[7]

References

  1. Redmond, Donald Eugene (1970). "Tobacco and Cancer: The First Clinical Report, 1761". New England Journal of Medicine. 282 (1): 18–23. doi:10.1056/NEJM197001012820105. ISSN 0028-4793.
  2. Witschi, H. (2001). "A Short History of Lung Cancer". Toxicological Sciences. 64 (1): 4–6. doi:10.1093/toxsci/64.1.4. ISSN 1096-6080.
  3. "Lung cancer in the Schneeberg mines: A reappraisal of the data reported by Harting and Hesse in 1879". Lung Cancer. 10 (5–6): 401. 1994. doi:10.1016/0169-5002(94)90770-6. ISSN 0169-5002.
  4. Doll R, Hill AB (1999). "Smoking and carcinoma of the lung. Preliminary report. 1950". Bull. World Health Organ. 77 (1): 84–93. PMC 2557577. PMID 10063665.
  5. "CDC - History of the Surgeon General's Report - Smoking & Tobacco Use".
  6. Der CJ, Krontiris TG, Cooper GM (1982). "Transforming genes of human bladder and lung carcinoma cell lines are homologous to the ras genes of Harvey and Kirsten sarcoma viruses". Proc. Natl. Acad. Sci. U.S.A. 79 (11): 3637–40. PMC 346478. PMID 6285355.
  7. Veale, D; Ashcroft, T; Marsh, C; Gibson, GJ; Harris, AL (1987). "Epidermal growth factor receptors in non-small cell lung cancer". British Journal of Cancer. 55 (5): 513–516. doi:10.1038/bjc.1987.104. ISSN 0007-0920.